

Vidac Pharma Receives Renewed “Buy” Rating from Sphene Capital Following German Authorization for New Phase 2 AK Trial

Vidac wins renewed “Buy” rating as Phase 2 AK trial gets green light in Germany -analysts see major upside ahead.

LONDON, UNITED KINGDOM,
November 21, 2025 /

EINPresswire.com/ -- Vidac Pharma Holdings Plc., a clinical-stage oncology company pioneering first-in-class therapies targeting the unique metabolism of cancer cells, is pleased

to announce that [Sphene Capital](#), the highly respected European independent analyst house, has once again issued a “Buy” recommendation for Vidac Pharma’s shares. The reaffirmed rating comes with no change in the analyst’s GBP-based valuation of the Company. The target price has been adjusted slightly from €4.20 to €4.10 per share, reflecting currency movements between the British Pound and Euro, while maintaining confidence in the Company’s long-term value.

“

Their continued confidence highlights the clear direction of our program as we move toward a Phase 3 trial”

Dr. Max Herzberg

This renewed “Buy” recommendation follows the recent regulatory authorization in Germany to initiate Vidac Pharma’s new Phase 2 clinical study in actinic keratosis (AK), focusing specifically on highly proliferative lesions—a clinically significant patient segment with considerable

unmet need.

Dr. Max Herzberg, Founder and CEO of Vidac Pharma, commented:

“We are proud that a high-quality analyst group such as Sphene Capital, through their understanding of our science, recognizes the importance of this new claim for our future market positioning. Their continued confidence highlights the clear direction of our program as we move toward a Phase 3 trial.”



Vidac Pharma remains committed to advancing its innovative Tuvatexib (VDA-1102) platform as it continues to develop first-in-class therapies addressing the abnormal metabolic pathways of cancer and pre-cancerous skin lesions.

To read the complete Sphene Capital analysis, please click the link

<https://vidacpharma.com/en/investor-relations>

Max Herzberg

Vidac pharma Holding Plc

+972 54-425-7381

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/869142494>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.